Awards for translational research
24 September, 2014A national prize and four awards are being offered by the Translation Research Institute to support translational research.
Starpharma raising $23m for clinical programs
23 September, 2014 by Dylan Bushell-EmblingStarpharma (ASX:SPL) is conducting an up to $23m placement and plans to use part of the proceeds to help fund clinical trials of VivaGel and DEP docetaxel.
MS research alliance
19 September, 2014Multiple Sclerosis Research Australia has joined a global alliance to work towards better understanding and treating progressive multiple sclerosis.
Call for ideas to partner with GSK
15 September, 2014GSK is calling for Australian and New Zealand researchers and start-up companies to submit ideas for potential partnership opportunities.
Virax seeks to reactivate IND for cancer drug
11 September, 2014 by Dylan Bushell-EmblingVirax (ASX:VHL) has received a technical assessment that will allow it to start the process of reactivating the US IND application for cancer drug GGTI-2418.
Ascend to begin breast cancer, BCC trials in '15
08 September, 2014 by Dylan Bushell-EmblingAscend Biopharmaceuticals aims to commence a phase II trial of BCC treatment candidate ASN-002 in 1H15 and a phase Ib trial of breast cancer candidate ASN-004 in 2H15.
Plants help create happy office vibes
05 September, 2014Putting plants in the office makes for happier staff and boosts productivity.
Phylogica, IMB get $500K grant for cancer drug project
04 September, 2014 by Dylan Bushell-EmblingPhylogica and the UQ's Institute for Molecular Bioscience have picked up grant funding for a project to screen for potential new antimetastatic drugs.
More funding for medical research
03 September, 2014New treatments, improved research translation and Indigenous youth suicide are some of the areas to benefit from the latest NHMRC grant announcement.
Minomic forges prostate cancer partnership
02 September, 2014 by Dylan Bushell-EmblingMinomic International and US-based Catalent Pharma Solutions will jointly develop the former's MIL-38 antibody drug conjugate into a potential new treatment for prostate cancer.
Alchemia loss grows on lower fondaparinux sales
02 September, 2014 by Dylan Bushell-EmblingAlchemia's (ASX:ACL) share of the profits from sales of anti-coagulant generic fondaparinux declined in FY14, but the company expects business to pick up from 2015.
Imugene names Charles Walker as new CEO
26 August, 2014 by Dylan Bushell-EmblingFormer Alchemia (ASX:ACL) chief Charles Walker has taken the role of Imugene (ASX:IMU) CEO, to help lead the company's efforts to commercialise HER-Vaxx in gastric cancer.
Sirtex profit grows 30% in FY14
21 August, 2014 by Dylan Bushell-EmblingSirtex Medical (ASX:SRX) has posted a 30.6% increase in profit for FY14, as dose sales of its SIR-Spheres liver cancer treatment reached a record high.
Potential new standard of care for prostate cancer
21 August, 2014A potential new standard of care is emerging for prostate cancer with a new treatment combination significantly reducing the spread of the disease as well as limiting side effects.
Bioscience Managers' first fund achieves 24.7% IRR
15 August, 2014 by Dylan Bushell-EmblingBioscience Managers' first fund returned $1.76 per $1 invested, thanks to its portfolio which includes Alchemia (ASX:ACL) Bionomics (ASX:BNO), Acrux (ASX:ACR) and HeartWare (ASX:HIN).
